Literature DB >> 28093244

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

Kai Chen1, Fei Zhou2, Wenxiang Shen3, Tao Jiang2, Xue Wu4, Xiaoling Tong4, Yang W Shao4, Songbing Qin5, Caicun Zhou6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28093244     DOI： 10.1016/j.jtho.2016.12.024

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  32 in total

Review 1.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

2.  Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Authors:  Stephen R Fairclough; Lesli A Kiedrowski; Jessica J Lin; Ori Zelichov; Gabi Tarcic; Thomas E Stinchcombe; Justin I Odegaard; Richard B Lanman; Alice T Shaw; Rebecca J Nagy
Journal:  Exp Hematol Oncol       Date:  2019-10-11

Review 3.  Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Authors:  G M O'Kane; T A Barnes; N B Leighl
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 4.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Authors:  Tao Jiang; Chunxia Su; Shengxiang Ren; Federico Cappuzzo; Gaetano Rocco; Joshua D Palmer; Nico van Zandwijk; Fiona Blackhall; Xiuning Le; Nathan A Pennell; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 5.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

Review 6.  Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.

Authors:  Zhengyang Hu; Ming Li; Zhencong Chen; Cheng Zhan; Zongwu Lin; Qun Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12

7.  Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.

Authors:  Zhe Yang; Jinqi Yang; Yedan Chen; Yang W Shao; Xing Wang
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

8.  Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion.

Authors:  Fedor Moiseenko; Nikita Volkov; Alexey Bogdanov; Michael Dubina; Vladimir Moiseyenko
Journal:  F1000Res       Date:  2017-03-17

9.  Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Authors:  Xiuning Le; Sonam Puri; Marcelo V Negrao; Monique B Nilsson; Jacqulyne Robichaux; Theresa Boyle; J Kevin Hicks; Katherine L Lovinger; Emily Roarty; Waree Rinsurongkawong; Ming Tang; Huiying Sun; Yasir Elamin; Lara C Lacerda; Jeff Lewis; Jack A Roth; Stephen G Swisher; J Jack Lee; William N William; Bonnie S Glisson; Jianjun Zhang; Vassiliki A Papadimitrakopoulou; Jhanelle E Gray; John V Heymach
Journal:  Clin Cancer Res       Date:  2018-09-18       Impact factor: 12.531

Review 10.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.